Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Rho/ROCK Pathway Modulation

Executive Summary: Y-27632 dihydrochloride is a small-molecule inhibitor with high selectivity for Rho-associated protein kinases ROCK1 and ROCK2, demonstrating IC₅₀ values of 140 nM and Ki values of 300 nM, respectively (APExBIO). It inhibits Rho/ROCK signaling, disrupts actin stress fiber formation, and modulates cell cycle progression and cytokinesis (Ren et al., 2025). Y-27632 is widely adopted in studies of cancer invasion, stem cell viability, and cytoskeletal dynamics. The compound exhibits over 200-fold selectivity against kinases such as PKC and MLCK. Its solubility and storage profile make it practical for diverse in vitro and in vivo protocols (APExBIO).

Biological Rationale

Rho-associated kinases (ROCK1 and ROCK2) are central regulators of actin cytoskeleton reorganization, cell contraction, and tight junction integrity. Activation of the RhoA/ROCK pathway leads to myosin light chain (MLC) phosphorylation and stress fiber assembly, mediating cell motility, proliferation, and morphogenesis (Ren et al., 2025). Dysregulation of this pathway is implicated in cancer metastasis, fibrotic disorders, and infectious diseases. Inhibition of ROCK signaling has demonstrated efficacy in attenuating pathological processes such as tumor invasion and abnormal cytokinesis. Y-27632 dihydrochloride enables precise, selective suppression of ROCK1/2 activity, facilitating mechanistic studies and translational research in oncology, regenerative medicine, and virology. The compound's specificity minimizes off-target kinase inhibition, supporting reproducible experimental outcomes (APExBIO).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a cell-permeable inhibitor that binds the catalytic domains of ROCK1 and ROCK2, suppressing their kinase activity. The inhibitory constants are IC₅₀ ≈ 140 nM for ROCK1 and Ki ≈ 300 nM for ROCK2 (APExBIO). The compound disrupts phosphorylation of downstream substrates, including myosin light chain, leading to reduced actomyosin contractility and loss of stress fibers (Ren et al., 2025). This effect impairs cell adhesion, motility, and tight junction stability. In the context of viral entry, such as Minute Virus of Canines (MVC) infection, inhibition of ROCK1 prevents the virus-induced dissociation of tight junctions and occludin translocation (Ren et al., 2025). Y-27632 exhibits over 200-fold selectivity against other kinases, including PKC, cAMP-dependent protein kinase, MLCK, and PAK.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with an IC₅₀ of approximately 140 nM and ROCK2 with a Ki of 300 nM, providing over 200-fold selectivity versus kinases such as PKC and MLCK (APExBIO).
• Y-27632 blocks RhoA/ROCK1/MLC2-mediated dissociation of tight junctions in WRD canine cells, reducing viral protein expression and genomic copy number during MVC infection (Ren et al., 2025).
• The compound is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25°C; solubility is enhanced by warming to 37°C or an ultrasonic bath (APExBIO).
• Y-27632 suppresses proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (10–100 μM, 24–72 h) (APExBIO).
• In vivo, Y-27632 reduces tumor invasion and metastasis in mouse models of cancer, as measured by histopathological analysis and metastatic burden (Related Article).
• ROCK pathway inhibition by Y-27632 enhances stem cell viability and survival during passaging, as demonstrated in human pluripotent stem cell cultures (see Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Adv...).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is a benchmark tool for dissecting the Rho/ROCK signaling pathway in vitro and in vivo. Its primary applications include:

• Disruption of Rho-mediated actin stress fiber formation and cytoskeletal remodeling.
• Enhancement of stem cell viability and cloning efficiency during passaging (Internal Reference).
• Suppression of tumor cell invasion and metastasis in preclinical models.
• Analysis of cell proliferation, cytokinesis, and cell cycle transitions.
• Investigation of tight junction integrity and host–pathogen interactions (Ren et al., 2025).

This article provides updated, cross-disciplinary guidance compared to Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for ..., which focuses on foundational selectivity data. Here, we integrate new findings relevant to viral infection models and practical workflow parameters.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit all kinases involved in actin dynamics; its selectivity is restricted to ROCK1/2, and it is >200-fold less potent against PKC, MLCK, and PAK.
• The compound's effects on cell proliferation and migration are context-dependent; some cell types may show variable sensitivity.
• Long-term storage of Y-27632 stock solutions (>2 months) at room temperature can lead to degradation; always store desiccated at 4°C or below.
• Y-27632 is not a universal antiviral; its effect on viral entry is specific to contexts where Rho/ROCK signaling mediates tight junction remodeling, such as MVC infection (Ren et al., 2025).
• High concentrations may induce off-target effects; titrate according to published benchmarks and cell-type specific responses.

Workflow Integration & Parameters

Y-27632 dihydrochloride (SKU: A3008, product page) is supplied as a solid and should be dissolved in DMSO, ethanol, or water at concentrations up to 111.2 mg/mL, 17.57 mg/mL, or 52.9 mg/mL, respectively. Warming to 37°C or using an ultrasonic bath can aid dissolution. Stock solutions should be aliquoted and stored below –20°C for up to several months; avoid repeated freeze-thaw cycles. For in vitro assays, working concentrations typically range from 1 μM to 100 μM, depending on cell type and endpoint. In stem cell culture, 10 μM is standard for survival during passaging (Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Adv...), while cancer invasion assays may require 10–50 μM for 24–72 hours. For in vivo dosing, refer to published protocols and titrate according to species and model. For further optimization, see Y-27632 Dihydrochloride empowers researchers..., which focuses on troubleshooting and protocol flexibility. This article extends those recommendations by integrating evidence from virology and tight junction studies.

Conclusion & Outlook

Y-27632 dihydrochloride remains a gold-standard, highly selective inhibitor of ROCK1 and ROCK2. Its nanomolar potency, broad utility in cytoskeletal, cancer, and stem cell research, and robust evidence base support its continued use as an experimental benchmark. The compound's ability to modulate Rho/ROCK signaling underpins its value in mechanistic studies and translational applications. Future work will likely expand its use in organoid models, regenerative medicine, and emerging pathogen research, as underscored by APExBIO's ongoing commitment to product quality and scientific rigor.